Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. et al
Case Number:
2:21-cv-02111
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Sectors & Industries:
-
January 31, 2022
Celgene, Dr. Reddy's Settle Generic Cancer Drug Row
Bristol-Myers Squibb subsidiary Celgene has settled litigation in the U.S. that sought to block Indian drugmaker Dr. Reddy's from marketing generic versions of its blockbuster cancer medication Pomalyst, according to documents that the two sides filed on Friday in New Jersey federal court.
-
February 09, 2021
Celgene Sues Dr. Reddy's To Block Cancer Drug Generic
Celgene has hit Dr. Reddy's Laboratories with a lawsuit in New Jersey federal court seeking to block the Indian drugmaker from marketing generic versions of the Bristol-Myers Squibb unit's blockbuster cancer medication Pomalyst.